Comparative study of the effect of vortioxetine on sexual function in outpatient patients with non-psychotic depression

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: The negative effect of sexual dysfunction on the quality of life is often underestimated, although it is one of the determinants of antidepressant tolerance. According to the results of international studies, the prevalence of sexual dysfunction in patients with depression treated with selective serotonin reuptake inhibitors or selective serotonin and norepinephrine reuptake inhibitors is 27–65% in women and 26–57% in men. Treatment with fewer adverse sexual effects should be considered a potential first-line option in patients with psychiatric condition interested in maintaining a sexual life.

AIM: To study the effects of vortioxetine and citalopram on the sexual function of outpatients with non-psychotic depression.

MATERIALS AND METHODS: The study was conducted based on the Center for Psychosomatic Medicine and Psychotherapy. We examined 134 patients (mean age, 35.8±7.6 years) who underwent outpatient treatment by a psychiatrist. Among them, 71 patients received vortioxetine, 45 patients had depressive states of endogenous origin (15 patients with affective disorders and 30 patients with schizotypal disorder), and 26 patients had adjustment disorder. Citalopram was administered in 63 patients: 39 with depressive conditions within endogenous diseases (18 with affective disorders and 21 with schizotypal disorder) and 24 patients with adjustment disorder. The study lasted for 6 weeks, after which sexual function was assessed.

RESULTS: In the groups taking vortioxetine and citalopram, significant differences were found in the incidence of sexual dysfunction: the use of vortioxetine compared with citalopram allowed patients to maintain libido and orgasmic function and, in some cases, helped restore the sexual sphere.

CONCLUSION: The data obtained showed that vortioxetine was statistically significantly more favorable in relation to sexual function.

Full Text

Restricted Access

About the authors

Victoria Yu. Krylatykh

Center for Psychosomatic Medicine and Psychotherapy

Author for correspondence.
Email: ssamara@yandex.ru
ORCID iD: 0000-0002-3583-6962
SPIN-code: 6734-8701
Russian Federation, Moscow

Galina A. Aleshkina

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: aleshkina-ga@yandex.ru
ORCID iD: 0000-0002-8872-9810
SPIN-code: 7477-8598

Dr. Sci. (Med.), professor

Russian Federation, Moscow

References

  1. World Health Organization. Depression. [Internet]. [cited 2022 Jun 4]. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/depression
  2. Steffen A, Thom J, Jacobi F, et al. Trends in prevalence of depression in Germany between 2009 and 2017 based on nationwide ambulatory claims data. J Affect Disord. 2020;271:239–247. doi: 10.1016/j.jad.2020.03.082
  3. Smulevich AB. Depressija kak obshhemedicinskaja problema: voprosy kliniki i terapii. Psychiatry and Psychopharmacotherapy. 2006;8(3):4–10. (In Russ).
  4. Bunjkova KM, Izumina TA, Repin SA. Formation of remission and life quality of patients with nonpsychotic depressions. Bulletin of Neurology, Psychiatry and Neurosurgery. 2014;8:3–7. (In Russ).
  5. Kursakov AA, Bobrov AE. Depressii s unipoljarnym i bipoljarnym techeniem v uslovijah pervichnoj medikosanitarnoj pomoshhi: klinicheskie, povedencheskie osobennosti i ishody terapii. Sovremennaja terapija psihicheskih rasstrojstv. 2016;4:2–10. (In Russ).
  6. Shchukina EP, Bunkova KM, Izotova EA, Goncharova EM. Comparative study of the efficacy of venlafaxine and amitriptylline in patients with anxious depressions. Rossiiskii meditsinskii zhurnal (Medical Journal of the Russian Federation, Russian Journal). 2012;18(2):21–24. (In Russ).
  7. Jacobsen PL, Nomikos GG, Zhong W, et al. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr. 2020;25(1):50–63. doi: 10.1017/S1092852919000750
  8. Wang SM, Han C, Bahk WM, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–112. doi: 10.4068/cmj.2018.54.2.101
  9. Edinoff AN, Akuly HA, Hanna TA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387–401. doi: 10.3390/neurolint13030038
  10. Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol. 2018;8(1):13–23. doi: 10.1177/2045125317720642
  11. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. 2018;17(1):3–11. doi: 10.1002/wps.20509
  12. Ramic E, Prasko S, Gavran L, Spahic E. Assessment of the antidepressant side effects occurrence in patients treated in primary care. Mater Sociomed. 2020;32(2):131–134. doi: 10.5455/msm.2020.32.131-134
  13. Torchinov AM, Bardenshtejn LM, Umahanova MM, Harharova MA. Sovremennye aspekty depressivnyh rasstrojstv u zhenshhin v perimenopauze. Zhurnal Rossijskogo obshhestva akusherov-ginekologov. 2006;3:34–38. (In Russ).
  14. Basson R, Gilks T. Women’s sexual dysfunction associated with psychiatric disorders and their treatment. Womens Health (Lond). 2018;14:1745506518762664. doi: 10.1177/1745506518762664
  15. Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I. Functional selectivity and antidepressant activity of serotonin 1A receptor ligands. Int J Mol Sci. 2015;16(8):18474–18506. doi: 10.3390/ijms160818474
  16. Chen C, Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: a systematic review and network meta-analysis. Psychiatry Res. 2019;281:112595. doi: 10.1016/j.psychres.2019.112595
  17. Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, impairs sexual functioning compared with placebo in healthy adults: a randomized, controlled trial. J Sex Med. 2019;16(10):1638–1649. doi: 10.1016/j.jsxm.2019.06.018
  18. Baldwin DS, Chrones L, Florea I, et al. The safety and tolerabi lity of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252. doi: 10.1177/0269881116628440

Supplementary files

Supplementary Files
Action
1. Fig. The state of orgastic function in the comparison groups, %

Download (87KB)

Copyright (c) 2022 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 01016 от 19.07.1995 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies